SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile shares are facing significant volatility following an orbital insertion failure during a Blue Origin launch, where the latest BlueBird satellite was placed into an unsustainable low orbit. The community is actively debating the reliability of Blue Origin as a launch partner compared to SpaceX, while long-term investors are highlighting the company's insurance coverage and the upcoming backlog of satellites as reasons to maintain their bullish thesis.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors rally around the company's recent Greenland-approved consolidation of its 92.5% stake in the Tanbreez rare earth project. The community is focused on the potential for a massive short squeeze and the strategic importance of the asset, while debating whether current momentum will sustain a long-term re-rating.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as investors rally around the company's expanding role in AI infrastructure, specifically its custom ASIC development and optical networking capabilities. Community conversation is heavily focused on the stock's recent price momentum, a major strategic investment from Nvidia, and growing speculation about collaborative chip development with Google.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is currently attracting intense community attention as traders debate the potential for a massive volatility spike fueled by the escalating Iran conflict and the closure of the Strait of Hormuz. Investors are closely monitoring geopolitical tensions, questioning the sustainability of market valuations, and hedging against potential black swan events while navigating the ETF's inherent structural decay.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

$COCK is generating significant buzz as its dedicated community champions a unique model that integrates real-world business revenue from the 'Cocky Wings' food brand to support token buybacks. Investors are actively discussing this blend of memecoin culture and tangible business operations, with the 'Flock' emphasizing its long-term potential for passive income and upcoming development announcements.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing high volatility and intense social media discussion following news of an executive order aimed at fast-tracking research into psychedelics like ibogaine. The community is actively debating the stock's potential for a short squeeze, fueled by its low float and heavy short interest, while some market participants urge caution, labeling the rally as a speculative 'buy the rumor, sell the news' event.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is seeing heightened retail interest and speculation as investors weigh the potential of its large-scale AI energy infrastructure project against concerns over its pre-revenue status and the recent departure of its CEO. Community discussion is currently focused on the company's long-term growth prospects, active searches for anchor tenants, and the volatility triggered by leadership changes and insider trading activity.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is facing intense bearish sentiment driven by the rapid rise of AI design alternatives and structural fears regarding the long-term viability of its creative SaaS model. While bulls point to pristine financials and aggressive share buybacks as a generational buying opportunity at historic valuation lows, the community remains divided over whether the company is successfully embedding AI into its ecosystem or simply failing to innovate against newer, agile competitors.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is experiencing intense investor scrutiny as the semiconductor sector continues its rapid, parabolic ascent, leaving many bearish traders facing significant losses. The community is deeply divided, with some investors betting on a near-term correction due to geopolitical tensions and perceived overvaluation, while others are capitulating and shifting into bullish positions to capitalize on the relentless sector momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul><li>Tariffs on drugs imported from countries with which the U.S. has tariff deals, such as the European Union, South Korea, Japan, and UK, will be capped at 15%.</li><li>The White House said that the duties will apply to products made by certain large pharma companies in 120 days while smaller ones will get 60 more days.</li></ul> President Donald J. Trump on Thursday signed an executive order imposing a 100 percent tariff on imported patented pharmaceuticals and active pharmaceutical ingredients, citing a national-security threat from America’s heavy dependence on foreign supply chains, as the administration seeks to increase manufacturing in the country.Pharmaceutical ETFs iShares US Pharmaceuticals ETF (IHE) and VanEck Pharmaceutical ETF (PPH) closed 0.75% and 0.45%, respectively, following the announcement.<h2 class="st-heading-2">New Levies</h2>Despite leading the world in pharmaceutical research and development, U.S. produces only 15 percent of the active pharmaceutical ingredients it uses for patented medicines and imports 53 percent of the finished patented products themselves, the White House said.The new levies apply to patented drugs made in countries with which the U.S. have no tariff deals and by companies that haven’t inked drug pricing deals with the administration. Tariffs on drugs imported from countries with which the U.S. has tariff deals, such as the European Union, South Korea, Japan, and UK, will be capped at 15%.The White House said that the duties will apply to products made by certain large pharma companies in 120 days while smaller ones will get 60 more days.<h2 class="st-heading-2">How Can Companies Avoid These Levies?</h2>Companies can sharply reduce or avoid the tariff by committing to onshore production or signing drug pricing agreements with the Department of Health and Human Services, Trump said.Firms that submit approved onshoring plans will initially face only a 20 percent tariff. Those inking pricing agreements with the government and onshoring production will pay no tariffs at all through Jan. 20, 2029, Trump said.Several companies have already inked drug pricing agreements with the Trump administration, including Merck, Pfizer and Eli Lilly and Company, leaving select big names and many small and mid-sized pharma companies exposed.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IHE">IHE</a> and <a href="https://stocktwits.com/symbol/PPH">PPH</a> stayed within the ‘neutral’ territory coupled with ‘normal’ message volume.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-tumbles-following-q1-delivery-miss-street-weighs-in/cZ7U4aORI8H">TSLA Stock Tumbles 5% Following Q1 Delivery Miss — Street Weighs In On Demand, Potential Discounts, AI Strategy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

President Donald Trump delivers his State of the Union address to a joint session of Congress in the chambers of the U.S. House of Representatives in Washington, DC on February 24, 2026. 

Trump Slaps 100% Tariffs On Imported Patented Drugs, Sparing Companies That Onshore Or Cut Prices

The new levies apply to patented drugs made in countries with which the U.S. have no tariff deals and by companies that haven’t inked drug pricing deals with the administration.

Equity

The new levies apply to patented drugs made in countries with which the U.S. have no tariff deals and by companies that haven’t inked drug pricing deals with the administration.


<ul class="summary-bullets"><li>Pharmaceutical companies from the European Union, Japan, South Korea, Switzerland, and the U.K. will be subject to separate tariff rates under the bilateral deals they have entered into with the U.S.</li><li>Earlier, a Bloomberg report said the Trump administration could announce new pharma tariffs as early as Thursday.</li><li>The report stated that there may be exemptions for drugs used to treat certain diseases.</li></ul>The Trump administration is reportedly preparing to impose tariffs of up to 100% on drugs from pharmaceutical companies that have not yet struck deals with the White House.According to a CNBC&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/04/02/trump-pharmaceutical-tariffs-100percent.html">report</a>, the new tariffs will be imposed on both branded drugs and their active ingredients. However, companies can avoid these tariffs if they move their manufacturing to the U.S. or are currently negotiating a deal with the Trump administration.The&nbsp;<a href="https://stocktwits.com/symbol/PPH">VanEck Pharmaceutical ETF</a> (PPH) and the&nbsp;<a href="https://stocktwits.com/symbol/IHE">iShares U.S. Pharmaceuticals ETF</a> (IHE) were both down about 1% at the time of writing.<h2 class="st-heading-2">Generic Drugs To Escape Additional Tariffs, Says Report</h2>The report added that generic drugs will not be subject to any additional tariffs.Pharmaceutical companies from the European Union, Japan, South Korea, Switzerland, and the U.K. will be subject to separate tariff rates under the bilateral deals they have entered into with the U.S., the report stated.Earlier, a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-04-01/trump-administration-readies-new-tariffs-on-select-drugmakers">report</a> said the Trump administration could announce new pharma tariffs as early as Thursday. The report added that there may be exemptions for drugs used to treat certain diseases. President Trump is scheduled to sign executive orders at 2 p.m. ET on Thursday, but it is not yet known what those orders will be.The report added that these tariffs result from an investigation under Section 232 of the Trade Expansion Act. This rule addresses imports of a product that threatens the national security of the U.S.<h2 class="st-heading-2">Several Major Pharma Companies Have Struck Deals Already</h2>Several major pharmaceutical companies struck deals with the Trump administration in 2025 to lower the prices of their new and existing drugs in the U.S.This&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/abbvie-merck-top-drugmakers-lower-us-drug-prices-trump-mfn-deal/cLeitzkREsG">includes</a> giants such as Eli Lilly &amp; Co. (LLY), Novo Nordisk A/S (NVO), Pfizer Inc. (PFE), and GSK Plc. (GSK), and Merck &amp; Co. Inc. (MRK), among others.“As of today, 14 out of the 17 largest pharmaceutical companies… but they've all agreed… have now agreed to drastically lower drug prices for their American patients… for the American people and patients,” President Trump said, while announcing the deals in December 2025.In October 2025, President Trump said Pfizer would adopt most-favored-nation pricing for all new drugs launched in the U.S. The company launched its medicines on the TrumpRx portal in February 2026.In November 2025, Eli Lilly and Novo Nordisk struck an agreement with the Trump administration to cut prices on select upcoming pills and existing obesity drugs. Eli Lilly’s Zepbound, Novo Nordisk’s Ozempic, and Wegovy are available on the TrumpRx portal.Meanwhile, U.S. equities declined in Thursday morning’s trade. At the time of writing, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which tracks the S&amp;P 500 index, was down 0.22%, while the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) declined 0.34%. Retail sentiment on Stocktwits regarding the S&amp;P 500 ETF was in the ‘extremely bearish’ territory.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/owl-stock-sinks-blue-owl-blocks-4-2b-redemptions/cZ7xHowRI8h">OWL Stock Sinks After Blue Owl Reportedly Blocks Nearly $4.2B In Redemptions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Donald Trump is seen during the his departure the White House en route Hebron, Kentucky on March 11, 2026, in Washington DC, United States. (Photo by Celal Gunes/Anadolu via Getty Images)

Trump Administration Prepares Up To 100% Pharma Tariffs On Drugs From Companies That Have Not Struck A Deal Yet: Report

Pharmaceutical companies can avoid these tariffs if they move their manufacturing to the U.S. or are currently negotiating a deal with the Trump administration.

Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move

Eli Lilly's $2.75B AI drug deal with Insilico spotlights healthcare ETFs as investors seek diversified exposure to the fast-growing AI-driven pharma space. 

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

U.S. Food and Drug Administration vaccine chief Vinay Prasad is reportedly leaving the agency at the end of April.The Wall Street Journal <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/fdas-controversial-vaccines-chief-will-leave-the-agency-7fe59aa3">reported</a> the upcoming departure on Friday, citing FDA Commissioner Marty Makary.Shares of select pharmaceutical companies with whom Prasad has sparred with during his tenure rallied on the news. Shares of Moderna (<a href="https://stocktwits.com/symbol/MRNA">MRNA</a>) traded 3% higher after hours while uniQure (<a href="https://stocktwits.com/symbol/QURE">QURE</a>) stock rallied 50%. Shares of Sarepta Therapeutics (<a href="https://stocktwits.com/symbol/SRPT">SRPT</a>) also gained 5% in extended hours of trading.Makary said that federal health officials are now on the lookout for a replacement for Prasad who led the Center for Biologics Evaluation and Research (CBER) at the FDA. He was responsible for reviewing certain cancer drugs, gene therapies, and other treatments in addition to vaccines.<h2 class="st-heading-2">Prasad’s Shaky Tenure</h2>During his tenure, Prasad faced several disputes pertaining to drug reviews.Earlier this year, Prasad refused to consider an application seeking approval for Moderna’s flu shot but the agency later <a href="https://stocktwits.com/news-articles/markets/equity/moderna-stock-fda-accepts-revised-flu-vaccine-application-for-review/cZR0MwoR4v1">pivoted</a> after Moderna agreed on another confirmation study post-approval.Most recently, the FDA has gone up against uniQure’s gene therapy for ⁠Huntington's disease. The agency has <a href="https://stocktwits.com/news-articles/markets/equity/why-did-qure-stock-almost-halve-pre-market-today/cZd344CRIcD">recommended</a> that the company conduct a sham-surgery-controlled study after disagreeing with other study data submitted.Prasad previously <a href="https://stocktwits.com/news-articles/markets/equity/fda-official-who-halted-sarepta-s-gene-therapy-resigns-amid-backlash-over-access-to-duchenne-treatment/choQYmjR5yz">resigned</a> in July 2025 merely months into the job following controversies over decisions on Sarepta Therapeutics’ Elevidys gene therapy for Duchenne muscular dystrophy. Prasad was brought back shortly afterwards.<h2 class="st-heading-2">Reasons For Exit</h2>Regarding Prasad’s departure this term, Makary reportedly said that he had only intended to remain at the agency during his period of absence at the University of California.As per the agency commissioner, all policies that Prasad wanted to help implement have now been announced, including a new priority program to expedite the application review process for treatments that meet national priorities.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/incyte-drug-approved-in-europe-for-treating-yet-another-rare-cancer/cZdLgTHRI49">Incyte’s Drug Approved In Europe For Treating Yet Another Rare Cancer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

QURE, SRPT, MRNA Shares Rally On Report Of Vinay Prasad’s FDA Exit

The Wall Street Journal reported the upcoming departure on Friday, citing FDA Commissioner Marty Makary.

TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint

TBPH company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

<ul class="summary-bullets"><li>Makary urged the Trump administration to partner with the pharmaceutical industry.&nbsp;</li><li>The senior official is of the opinion that there exists multiple bottlenecks that have caused the U.S. to lag behind.&nbsp;</li><li>As per CNBC, China now conducts more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals.</li></ul>The U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Wednesday reportedly warned that the country is falling behind its Asian rival China in drug development.Makary, in an <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/02/18/fda-chief-warns-us-is-losing-ground-to-china-in-early-drug-trials.html">interview</a> with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.The senior official is of the opinion that there exists multiple bottlenecks that have caused the U.S. to lag behind. Makary recommended that the Trump administration partner with the pharmaceutical industry “to help them deliver more cures and meaningful treatments for the American public.”As per CNBC, China now conducts more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals.<h2 class="st-heading-2">FDA’s Efforts</h2>Last year, the FDA initiated a program called the Commissioner's National Priority Voucher program in a bid to expedite the review of certain drug applications. The program aims to reduce FDA assessment time to one to two months from the standard 10 to 12 months.So far, over 15 drugs from various pharma companies have been awarded the voucher and while one has been approved, another has also been rejected.Earlier this month, FDA refused to approve Disc Medicine’s bitopertin oral tablets for the treatment of Erythropoietic Protoporphyria despite tapping the drug for fast review.However, the agency approved Augmentin XR manufactured by USAntibiotics in December after granting it the voucher. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/IHE"> iShares U.S. Pharmaceuticals ETF</a> (IHE) stayed within the ‘neutral’ territory coupled with ‘normal’ message volume.The ETF closed marginally in the red on Wednesday but has gained about 29% over the past 12 months.Meanwhile, Invesco Pharmaceuticals ETF (PJP) and State Street SPDR S&amp;P Pharmaceuticals ETF (XPH) added 26% and 27%, respectively.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/carvana-dismisses-short-seller-allegations-as-misleading/cZRK3kWR4wG">Carvana Dismisses Short Seller Allegations As Misleading: Retailer’s Q4 Earnings Disappoint Wall Street</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Commissioner Marty Makary speaks at a news conference on removing synthetic dyes from America's food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. (Photo by Nathan Posner/Anadolu via Getty Images)

FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development

Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.

<ul class="summary-bullets"><li>The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S.&nbsp;</li><li>With this step, ART100 moves from regulatory clearance to active commercial availability, the company said.</li><li>Earlier, Inspira announced a non-binding term sheet for a proposed two-part deal to acquire an advanced liquid biopsy diagnostics business</li></ul>Shares of Inspira Technologies OXY (IINN) popped over 28% in pre-market trading on Monday after Israel’s largest health services provider approved the procurement of its FDA-cleared ART100 platform.<a href="https://stocktwits.com/symbol/IINN">IINN shares</a> gave up premarket gains and fell around 3% after the opening bell.&nbsp;The company secured approval from Clalit Health Services’ Medical Equipment Committee, allowing its INSPIRA ART100 system to be immediately procured and deployed across a healthcare network serving roughly 4.9 million members.<h2 class="st-heading-2">ART100 Regulatory Clearance</h2>With this step, ART100 moves from regulatory clearance to active commercial availability, marking a significant growth opportunity for Inspira and strong clinical validation.“By securing this approval, we are laying the foundation for potentially long-term, high-quality revenue. This validation from a world-class, data-driven health ecosystem serves as a powerful reference case as we accelerate our commercialization efforts in the U.S. and other global markets,” said Dagi Ben-Noon, CEO of Inspira Technologies.The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and for (Extracorporeal Membrane Oxygenation) ECMO procedures outside the U.S.<h2 class="st-heading-2">Top U.S. Medical Center Clears ART100&nbsp;</h2>In January, Inspira Technologies’ ART100 system completed clinical evaluation at a top U.S. academic medical centre and moved into the budgeted procurement stage. The system successfully treated about 30 patients across surgeries, transplants, and other critical procedures, leading to its adoption into routine clinical workflows.&nbsp;With the evaluation phase now closed, the hospital has begun an internal process to purchase multiple ART100 units, pending final budget approval.Earlier, Inspira announced a non-binding term sheet for a proposed two-part deal to acquire an advanced liquid biopsy diagnostics business. The transaction also includes a planned $15 million strategic equity investment.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.The stock has shed around 25% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Why Did IINN Stock Surge 28% In Pre-Market Today?

The company won approval from Clalit Health Services to deploy its INSPIRA ART100 system across a network of around 4.9 million members.

<ul class="summary-bullets"><li>Hims &amp; Hers said the compounded copy uses the same active ingredient as Wegovy but features a different formulation and delivery system.</li><li>The compounded pill will start at the introductory pricing for the first month for qualifying new customers under a five-month plan.</li><li>The pill is engineered to preserve the active ingredient during digestion and improve absorption.</li></ul>Shares of Hims &amp; Hers Health, Inc. (HIMS) rose 10% on Thursday after the company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.Hims &amp; Hers said the compounded copy uses the same active ingredient as Wegovy but features a different formulation and delivery system from the FDA-approved oral semaglutide. Novo Nordisk originally introduced Wegovy as a once-weekly injection and expanded the franchise earlier this year with the launch of an oral pill version.<h2 class="st-heading-2">$100 Cheaper Than Novo’s Wegovy</h2>Hims &amp; Hers said treatment plans using the compounded pill will start at an introductory $49 for the first month for qualifying new customers under a five-month plan. The remaining months are priced at $99 per month, payable in advance.According to Novo Nordisk’s website, Wegovy pills are priced at $149 per month for a 1.5 mg dose.Hims &amp; Hers stated that its compounded pill is engineered to preserve the active ingredient during digestion and improve absorption, offering an alternative for patients who want to avoid injections.Meanwhile, NVO shares fell nearly 6%.<h2 class="st-heading-2">Novo’s Pricing Challenges</h2>Earlier this week, Novo said it expects adjusted sales for full year 2026 to drop between 5% and 13%, with operating profit potentially falling by 13% due to pricing pressure, intensifying competition, and upcoming patent expiries for key ingredients in Wegovy and Ozempic in select markets outside the U.S.“Our 2026 guidance reflects a year of unprecedented pricing pressure,” CEO Mike Doustdar said in a call with journalists on Wednesday. Doustdar added that Novo would have to accept short-term pain to lift volumes, arguing that lowering prices would pay off in the long-run.The pill variant has already seen significant traction since its launch in January.“I can tell you, as of this week, we have over 170,000 people that are on the Wegovy pill, and most of that is self-pay,” Doustdar said in a call with analysts.Eli Lilly (LLY), the maker of weight-loss drugs Mounjaro and Zepbound, saw its shares fall 6.5%.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/HIMS">HIMS</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, while chatter was ‘extremely high’ on the platform.One user saw the new launch as a “trend changing event.”<stembedurl>https://stocktwits.com/Dr_Stoxx/message/644091407</stembedurl>Another bullish user highlighted HIM’s latest developments.<stembedurl>https://stocktwits.com/tothebulltothewall/message/644092695</stembedurl>Year-to-date, the stock has declined around 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-b-stock-is-falling-despite-q4-beat/cZbZB3uR4VV">Barrick’s Q4 Earnings Beat Expectations – So, What Is Dragging The Stock Down In Premarket Today?</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling?

The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.

HIMS Stock Rises On Low-Cost Wegovy Alternative, Raising New Pricing Questions For Novo And Lilly

The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.



<ul class="summary-bullets"><li>Eli Lilly issued a revenue guidance between $80 billion and $83 billion for fiscal 2026</li><li>For the full year 2025, Eli Lilly’s revenue grew 45% to $65.18 billion.</li><li>CFO Lucas Montarce said the company expects to launch the multidose Zepbound within the next 30 days, according to a Bloomberg report.</li></ul>Shares of Eli Lilly (LLY) jumped 8% in pre-market trading on Wednesday, after the company reported better-than-expected fourth-quarter results and issued a revenue guidance between $80 billion and $83 billion for fiscal 2026, significantly above fiscal 2025 revenue.<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> were up 9.2% after the opening bell.Fourth-quarter revenue surged 43% to $19.3 billion, driven by volume growth from Mounjaro and Zepbound – signalling sustained momentum in its obesity and diabetes portfolio. Analysts had expected a revenue of $17.86 billion, according to Fiscal.ai data. Meanwhile, Q4 earnings increased by 51% to $7.39 per share on a reported basis, compared to Street estimates of $7.22 per share.For the full year, Eli Lilly’s revenue grew 45% to $65.18 billion. LLY expects earnings of $33.50 to $35 per share for full-year 2026.<h2 class="st-heading-2">Mounjaro And Zepbound Drive Revenue Growth</h2>Global revenue for Mounjaro surged 110% to $7.4 billion in Q4 2025, with U.S. sales rising 57% to $4.1 billion on strong demand despite lower realized prices. International revenue jumped to $3.3 billion from $899 million a year earlier, driven mainly by volume growth.U.S. Zepbound revenue climbed 122% to $4.2 billion, fueled by higher demand but partially offset by pricing pressure. Meanwhile, revenue from Verzenio, Eli Lilly’s drug to treat metastatic breast cancer, edged up 3% to $1.6 billion.<h2 class="st-heading-2">Eli Lilly’s Product Pipeline</h2>After the FDA authorized Lilly to market Zepbound in a multidose device last month, CFO Lucas Montarce said the company expects to launch the multidose pen within the next 30 days, according to a report by Bloomberg on Wednesday.In an interview with CNBC last month, CEO Dave Ricks said the upcoming Medicare coverage for obesity drugs could significantly boost the launch of its experimental weight-loss pill, Orforglipron. Ricks added that the company expects Medicare coverage to begin immediately after the drug’s launch.<h2 class="st-heading-2">LLY Pulls Ahead As NOVO Faces Headwinds</h2>Eli Lilly’s optimistic outlook stands in stark contrast to Novo Nordisk (NVO), which expects adjusted sales to decline between 5% and 13% and operating profit to drop by up to 13%. The company cited pricing pressure, intensifying competition, and upcoming patent expiries for the key ingredients in Wegovy and Ozempic in select markets outside the U.S.“This is just more evidence they are dominating the category,” Mizuho’s Jared Holz told Bloomberg of Eli Lilly’s obesity market position. “Novo is playing from behind and everyone knows it.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/LLY_jpg_1dcca688cf.webp" alt="LLY.jpg" width="933" height="102"><figcaption>LLY's Sentiment Meter and Message Volumes on Feb. 4, 2026 | Source: Stocktwits</figcaption></figure>One user said that Lilly proved that with “a good product comes great demand.”<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/643931351</stembedurl>LLY shares have gained around 25% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-fda-higher-dose-wegovy-nvo-stock-outlook/cZbjThlR4ZM">Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

LLY Stock Surges On Q4  Beat – Obesity, Diabetes Drugs Drive Strong FY26 Outlook

LLY Stock - Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

IHE
iShares U.S. Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IHE News

IHEiShares U.S. Pharmaceuticals ETF